NETworking-The First Three Years of the World NET Cancer Awareness Day Alliance Abstract #728

Introduction: Neuroendocrine tumors have an incidence of 3-5/100,000 per year, however, many patients are diagonosed late in their clinical course resulting in poor outcomes and early death. Raising awareness of the myriad presenting symptoms with resultant early diagnosis is a priority health care initiative for this disease. In 2010, the World NET Cancer Day Awareness (WNCAD) Alliance was formed with the primary mission to raise awareness of neuroendocrine tumors and promote November 10 as World NET Cancer Awareness Day
Aim(s): To promote awareness, education and advocacy of neuroendocrine tumors through the development of a global alliance - WNCAD.
Materials and methods: The WNCAD Alliance and its member groups have for the last three years promoted awareness of NET cancers locally and globally with the unifying motto - 'if you don't suspect it, you won't detect it'. The development of an Internet presence, an evolving social network profile, utilization of traditional media, resource sharing and global NET patient education has resulted in significant improvements in awareness of neuroendocrine tumours internationally.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr John C Leyden

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1208 Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management: Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Guidelines support an MDT approach to NETs. We present data on the global NET pt perspective regarding MDT care.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Kjell Öberg
#2078 Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses
Introduction: In practice, many patients with NETs report a change in symptoms after starting somatostatin analogues (SSA’s). Many health professionals and NET patient advocates have noticed that some of the side effects experienced by patients are more common than patient information literature suggests. It is therefore important to ask what and how severe experiences are, and compare to literature, to help raise awareness amongst NET health professionals.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tara Whyand
Authors: Whyand T, Davies P, Bouvier C, ...
#1217 The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Despite a rising incidence of NETs, few studies document the NET pt experience. We present data on quality of life (QoL) and the global NET pt perspective.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Dr John Leyden
Keywords: Quality of life
#1220 Time to Diagnosis of Neuroendocrine Tumors (NETs): Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Diagnosis of NETs often occurs late in the disease course, which may have an impact on pt survival. We present pt-reported data on time to diagnosis in global NET pts.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Marianne Pavel
Keywords: Diagnosis
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden